查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371955

2030 年生物标记市场预测：按产品类型、适应症、服务、用途、最终用户和地区进行的全球分析

Biomarker Market Forecasts to 2030 - Global Analysis By Product (Consumables, Software and Services), Type (Safety Biomarkers, Validation Biomarkers and Efficacy Biomarkers), Indication, Service, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球生物标记市场规模为 581.2 亿美元，预计到 2030 年将达到 1,102.4 亿美元，预测期内年复合成长率为 14.2%。

生物标记是生物标记的简称，指检测、可量化的生物参数或特征，是生理或病理过程、疾病状态或治疗反应的指标。生物标记存在于多种生物样本中，包括血液、尿液、组织和其他体液。生物标记包括广泛的属性，包括遗传变异、基因表现模式、蛋白质水平、酶活性、代谢物浓度和影像特征。

根据中国卫生署公布的资料，约有2.03亿人患有心血管疾病，预计2030年这数字将增加73%。

癌症罹患率增加

癌症是一种复杂的疾病，由阶段致癌过程引起，涉及多个分子途径事件，使诊断、预后和治疗变得困难。癌症很复杂，因此没有单一的标记物是有效的。此外，不同类型的癌症具有不同的分子特征。新型生物标记的鉴定为开发旨在纠正癌症失调的治疗方法开闢了新途径。因此，由于生物标记研究的开拓和癌症罹患率的上升，全球市场预计将扩大。

严格法规

生物标誌物市场实行严格的规则和法规，以在医疗保健提供者、患者和相关人员之间建立信任和信心。这对于广泛采用基于生物标记的诊断和治疗至关重要。法规促进了生物标记开发、检验和应用的标准化。这些法规的复杂性使得它们对于做出资讯的医疗决策至关重要。因此，这个因素阻碍了市场的成长。

个人化医疗日益普及

个人化医疗依赖于识别患者疾病的特定遗传、分子和生化特征的生物标记。这些生物标记有助于确定最有效的治疗方法并最大限度地减少试验的需要。个人化医疗旨在透过根据每位患者的生物体质制定治疗方案来提高治疗效果。以生物标记为指导的个人个人化医疗可以根据患者的个别特征客製化药物给药和治疗方法，从而优化治疗结果。它透过提高患者参与度和满意度来推动市场成长，从而实现早期疾病检测和预防。

开发成本高

生物标誌物的开发需要大量资金和涉及科学家、临床医生、法规专家和其他专家的多学科方法。高开发成本反映了将可靠的生物标记物引入临床所需的复杂性和严格性。此外，生物标誌物的开发通常涉及一个漫长的迭代过程。此外，维持高品质品质、僱用熟练的科学家和建造技术基础设施都会产生额外的成本，从而阻碍市场需求。

COVID-19 的影响

COVID-19 大流行将对生物标记物产业产生适度的正面影响，因为生物标记物对于为 COVID-19 患者创造治疗方法至关重要。许多研究发现生物标记对于诊断和治疗至关重要。此外，一些组织还宣布了用于鉴定和治疗 COVID-19 的生物标记产品。这些新兴市场的开拓使得市场在疫情期间不断扩大。

肿瘤学领域预计在预测期内规模最大

癌症领域预计将出现良好的成长。生物标记在癌症诊断、预后和治疗中发挥重要作用。生物标记是检测的生物指标，可以提供有关癌症的存在、进展以及对某些治疗的反应性的资讯。它有助于鉴定肿瘤的特定分子或遗传特征，从而可以选择更有效的标靶治疗。从早期检测到治疗方法选择、监测和监测，生物标记有助于为癌症诊断和治疗提供更个体化和有效的方法。

诊断与研究实验室部门预计在预测期内年复合成长率最高

诊断与研究实验室领域预计在预测期内将以最高的年复合成长率成长。诊断实验室在监测疾病进展和评估治疗效果方面发挥重要作用。诊断和研究实验室在生物标记领域的进步中发挥着至关重要的作用。我们参与生物标记开发和应用过程的每阶段，从生物标记发现和检验到临床试验、检测开发和患者照护。他们的工作对诊断疾病、选择治疗方法和改善患者的治疗效果做出了重大贡献。

比最大的地区

由于高疾病负担、消费者对生物标记的认识不断提高、政府配合措施、技术突破和医疗保健基础设施的改善，预计北美在预测期内将占据最大的市场占有率。事实确实如此。在北美，美国占有最大的市场占有率。预计推动该地区成长的关键因素是该领域知名公司的存在以及他们正在进行的许多有机和无机项目。

复合年复合成长率最高的地区：

由于癌症罹患率、研究计画不断增加和临床试验成本低，预计亚太地区在预测期内将呈现最高的年复合成长率。生物标记在药物研发和药物开发过程中的应用正在推动新生物标记开发的研究投资。此外，对生物技术和製药公司的资助增加、合约研究组织数量的增加以及生物标誌物应用范围的扩大预计将在预测期内推动区域市场的成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球生物标记市场：副产品

  • 消耗品
  • 软体
  • 服务

第6章全球生物标誌物市场：依类型

  • 安全生物标记
  • 检验生物标记
  • 功效生物标记
    • 预测性生物标记
    • 替代生物标记
    • 动态生物标记
    • 预后生物标记

第7章全球生物标记市场：依适应症分类

  • 癌症
  • 心血管疾病
  • 感染疾病
  • 神经系统疾病
  • 免疫疾病
  • 其他适应症

第8章全球生物标记市场：依服务分类

  • 检测开发
  • 生物标记检验和测试
  • 样品製备
  • 其他服务

第9章全球生物标记市场：依用途

  • 药物研发发现与开发
  • 疾病诊断
    • 肿瘤学
    • 神经病学
    • 心臟病学
  • DNA指纹分析
  • 个人化医疗
  • 疾病风险评估
  • 其他用途

第10章全球生物标记市场：依最终用户分类

  • 製药和生物技术公司
  • 医院和专科诊所
  • 诊断和研究机构
  • 其他最终用户

第11章全球生物标誌市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第12章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第13章公司简介

  • GE Healthcare
  • Aushon Biosystem
  • Eisai Co. Limited
  • Abbott Laboratories, Inc.
  • Epistem Limited
  • Agilent Technologies Inc.
  • Roche Diagnostics Limited
  • Siemens AG
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific Inc.
  • Johnson & Johnson Services, Inc.
  • Epigenomics AG
  • QIAGEN
  • Enzo Biochem Inc
  • Charles River Laboratories International Inc.
  • Eurofins Scientific
  • LifeSign LLC
  • Bruker
  • Sino Biological Inc
  • Quest Diagnostics Incorporated
Product Code: SMRC24012

According to Stratistics MRC, the Global Biomarker Market is accounted for $58.12 billion in 2023 and is expected to reach $110.24 billion by 2030 growing at a CAGR of 14.2% during the forecast period. A biomarker, short for biological marker, refers to a measurable and quantifiable biological parameter or characteristic that serves as an indicator of a physiological or pathological process, a disease state, or a response to treatment. Biomarkers can be found in various biological samples, such as blood, urine, tissue, or other bodily fluids. Biomarkers can encompass a wide range of attributes, including genetic mutations, gene expression patterns, protein levels, enzyme activity, metabolite concentrations, and imaging features.

According to data published by ministry of health in China, about 203 million people are suffering from cardiovascular diseases and this number is expected to increase by 73% in 2030.

Market Dynamics:

Driver:

Increase in cancer incidence

Cancer is a complicated illness caused by a multi-stage carcinogenesis process with several molecular pathway events that make diagnosis, prognosis, and treatment difficult. A single marker is ineffective because cancer is complicated. Additionally, each kind of cancer has a unique molecular profile from the others. The identification of novel biomarkers opens up new avenues for the development of treatment approaches intended to correct dysregulation in cancer. As a result, the worldwide market will expand due to the development of biomarker research and the rising incidence of cancer.

Restraint:

Strict regulations

Strict rules and regulations are imposed to help build confidence and trust among healthcare providers, patients, and stakeholders in the biomarker market. This is crucial for the widespread adoption of biomarker-based diagnostics and therapies. Regulations promote standardization in the development, validation, and application of biomarkers. These regulations are complex and therefore become critical for making uninformed medical decisions. Thereby, this element hampers the market growth.

Opportunity:

Rising popularity of personalized medicine

Personalized medicine relies on biomarkers to identify specific genetic, molecular, or biochemical characteristics of a patient's disease. These biomarkers help determine the most effective treatment options, minimizing the need for trial-and-error approaches. By tailoring treatments to the individual patient's biological makeup, personalized medicine aims to increase treatment efficacy. Personalized medicine, guided by biomarkers, allows for the customization of drug dosage and treatment regimens based on individual patient characteristics, optimizing therapeutic outcomes. Its greater patient engagement and satisfaction followed up by early disease detection and prevention fuels the market growth.

Threat:

High development costs

The development of biomarkers requires significant financial investment and a multidisciplinary approach involving scientists, clinicians, regulatory experts, and other professionals. The high development costs reflect the complexity and rigor required to bring reliable biomarkers to clinical practice. Also, biomarker development often involves long and iterative processes; this prolonged timeline can result in cumulative costs. In addition, maintaining high standards of quality, recruiting skilled scientists and setting up technological infrastructure adds extra expenses which hinder the market demand.

COVID-19 Impact

The COVID-19 pandemic has a moderately beneficial effect on the biomarkers industry since biomarkers are essential for the creation of COVID-19 patient therapeutics. Biomarkers were discovered to be essential in the diagnosis and therapy in a number of studies. In addition, several organisations have introduced biomarker products to identify and treat COVID-19. These developments caused the market to expand throughout the pandemic era.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to have a lucrative growth. Biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They are measurable biological indicators that can provide information about the presence or progression of cancer, as well as the likely response to specific treatments. It can help identify specific molecular or genetic characteristics of a tumor, allowing for the selection of targeted therapies that are more likely to be effective. From early detection to treatment selection, monitoring and research, biomarker contributes to more personalized and effective approaches to cancer diagnosis and treatment.

The diagnostics & research laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostics & research laboratories segment is anticipated to witness the highest CAGR growth during the forecast period. Diagnostic labs play a vital role in monitoring disease progression and evaluating the effectiveness of treatments. Diagnostics and research laboratories play a pivotal role in advancing the field of biomarkers. They are involved in every stage of the biomarker development and application process, from discovery and validation to clinical testing, assay development, and patient care. Their work contributes significantly to improving disease diagnosis, treatment selection, and patient outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the high disease burden, rising consumer awareness of biomarkers, encouraging government efforts, technical breakthroughs, and improvements in healthcare infrastructure. In North America, the United States holds the largest market share. A significant element anticipated to fuel the region's growth is the presence of prominent firms in this area and the many organic and inorganic projects they have undertaken.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to its high prevalence of cancer, rising research initiatives, and low cost of clinical trials. Application of biomarkers in the drug discovery and development process is boosting key market players to invest in the research to develop novel biomarkers. In addition, an increase in funding for biotech and pharma companies, a rise in the number of CROs, and an increasing application scope of biomarkers are expected to facilitate regional market growth during the projected period.

Key players in the market:

Some of the key players profiled in the Biomarker Market include: GE Healthcare, Aushon Biosystem, Eisai Co. Limited, Abbott Laboratories, Inc., Epistem Limited, Agilent Technologies Inc., Roche Diagnostics Limited, Siemens AG, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., Johnson & Johnson Services, Inc., Epigenomics AG, QIAGEN, Enzo Biochem Inc, Charles River Laboratories International Inc., Eurofins Scientific, LifeSign LLC, Bruker, Sino Biological Inc and Quest Diagnostics Incorporated.

Key Developments:

In November 2022, Siemens is expanding its generator circuit-breaker portfolio with a new compact version - the HB1-Compact (HB1-C). The versatile and highly customizable solution uses maintenance-free vacuum switching technology and addresses the most challenging of constraints.

In September 2022, GE Healthcare, a medical technology, diagnostics, and digital solutions company, launched its 'Made in India', 'AI-powered' Cath lab-Optima IGS 320 to advance cardiac care in India. It is built at Wipro GE Healthcare's new Bengaluru factory and leverages the GE proprietary AutoRight technology.

Products Covered:

  • Consumables
  • Software
  • Services

Types Covered:

  • Safety Biomarkers
  • Validation Biomarkers
  • Efficacy Biomarkers

Indications Covered:

  • Cancer
  • Cardiovascular Disorders
  • Infectious Diseases
  • Neurological Disorders
  • Immunological Disorders
  • Other Indications

Services Covered:

  • Assay Development
  • Biomarker Validation & Testing
  • Sample Preparation
  • Other Services

Applications Covered:

  • Drug Discovery & Development
  • Disease Diagnostics
  • DNA Fingerprinting
  • Personalized Medicine
  • Disease Risk Assessment
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Specialty Clinics
  • Diagnostics & Research Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biomarker Market, By Product

  • 5.1 Introduction
  • 5.2 Consumables
  • 5.3 Software
  • 5.4 Services

6 Global Biomarker Market, By Type

  • 6.1 Introduction
  • 6.2 Safety Biomarkers
  • 6.3 Validation Biomarkers
  • 6.4 Efficacy Biomarkers
    • 6.4.1 Predictive Biomarkers
    • 6.4.2 Surrogate Biomarkers
    • 6.4.3 Pharmacodynamic Biomarkers
    • 6.4.4 Prognostic Biomarkers

7 Global Biomarker Market, By Indication

  • 7.1 Introduction
  • 7.2 Cancer
  • 7.3 Cardiovascular Disorders
  • 7.4 Infectious Diseases
  • 7.5 Neurological Disorders
  • 7.6 Immunological Disorders
  • 7.7 Other Indications

8 Global Biomarker Market, By Service

  • 8.1 Introduction
  • 8.2 Assay Development
  • 8.3 Biomarker Validation & Testing
  • 8.4 Sample Preparation
  • 8.5 Other Services

9 Global Biomarker Market, By Application

  • 9.1 Introduction
  • 9.2 Drug Discovery & Development
  • 9.3 Disease Diagnostics
    • 9.3.1 Oncology
    • 9.3.2 Neurology
    • 9.3.3 Cardiology
  • 9.4 DNA Fingerprinting
  • 9.5 Personalized Medicine
  • 9.6 Disease Risk Assessment
  • 9.7 Other Applications

10 Global Biomarker Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmaceutical & Biotechnology Companies
  • 10.3 Hospitals & Specialty Clinics
  • 10.4 Diagnostics & Research Laboratories
  • 10.5 Other End Users

11 Global Biomarker Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 GE Healthcare
  • 13.2 Aushon Biosystem
  • 13.3 Eisai Co. Limited
  • 13.4 Abbott Laboratories, Inc.
  • 13.5 Epistem Limited
  • 13.6 Agilent Technologies Inc.
  • 13.7 Roche Diagnostics Limited
  • 13.8 Siemens AG
  • 13.9 Bio-Rad Laboratories
  • 13.10 Thermo Fisher Scientific Inc.
  • 13.11 Johnson & Johnson Services, Inc.
  • 13.12 Epigenomics AG
  • 13.13 QIAGEN
  • 13.14 Enzo Biochem Inc
  • 13.15 Charles River Laboratories International Inc.
  • 13.16 Eurofins Scientific
  • 13.17 LifeSign LLC
  • 13.18 Bruker
  • 13.19 Sino Biological Inc
  • 13.20 Quest Diagnostics Incorporated

List of Tables

  • Table 1 Global Biomarker Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Biomarker Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Biomarker Market Outlook, By Safety Biomarkers (2021-2030) ($MN)
  • Table 4 Global Biomarker Market Outlook, By Validation Biomarkers (2021-2030) ($MN)
  • Table 5 Global Biomarker Market Outlook, By Efficacy Biomarkers (2021-2030) ($MN)
  • Table 6 Global Biomarker Market Outlook, By Predictive Biomarkers (2021-2030) ($MN)
  • Table 7 Global Biomarker Market Outlook, By Surrogate Biomarkers (2021-2030) ($MN)
  • Table 8 Global Biomarker Market Outlook, By Pharmacodynamic Biomarkers (2021-2030) ($MN)
  • Table 9 Global Biomarker Market Outlook, By Prognostic Biomarkers (2021-2030) ($MN)
  • Table 10 Global Biomarker Market Outlook, By Indication (2021-2030) ($MN)
  • Table 11 Global Biomarker Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 12 Global Biomarker Market Outlook, By Cardiovascular Disorders (2021-2030) ($MN)
  • Table 13 Global Biomarker Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 14 Global Biomarker Market Outlook, By Neurological Disorders (2021-2030) ($MN)
  • Table 15 Global Biomarker Market Outlook, By Immunological Disorders (2021-2030) ($MN)
  • Table 16 Global Biomarker Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 17 Global Biomarker Market Outlook, By Service (2021-2030) ($MN)
  • Table 18 Global Biomarker Market Outlook, By Assay Development (2021-2030) ($MN)
  • Table 19 Global Biomarker Market Outlook, By Biomarker Validation & Testing (2021-2030) ($MN)
  • Table 20 Global Biomarker Market Outlook, By Sample Preparation (2021-2030) ($MN)
  • Table 21 Global Biomarker Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 22 Global Biomarker Market Outlook, By Application (2021-2030) ($MN)
  • Table 23 Global Biomarker Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
  • Table 24 Global Biomarker Market Outlook, By Disease Diagnostics (2021-2030) ($MN)
  • Table 25 Global Biomarker Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 26 Global Biomarker Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 27 Global Biomarker Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 28 Global Biomarker Market Outlook, By DNA Fingerprinting (2021-2030) ($MN)
  • Table 29 Global Biomarker Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 30 Global Biomarker Market Outlook, By Disease Risk Assessment (2021-2030) ($MN)
  • Table 31 Global Biomarker Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 32 Global Biomarker Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 Global Biomarker Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 34 Global Biomarker Market Outlook, By Hospitals & Specialty Clinics (2021-2030) ($MN)
  • Table 35 Global Biomarker Market Outlook, By Diagnostics & Research Laboratories (2021-2030) ($MN)
  • Table 36 Global Biomarker Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.